$150 Million Accelerates Scientific Concepts Starting in Respiratory and Immunology Medicines and Vaccines

In Influenza Vaccine News by Influenza Vaccine

GSK plc and Flagship Pioneering today announced they have entered a collaboration to discover and develop a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance combines GSK’s disease area expertise and development capability with Flagship’s ecosystem of bioplatform companies, including its novel modalities and technologies, to make significant advances in healthcare.

Read More